Journal article

Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity

Adam W Nelson, Arnoud J Groen, Jodi L Miller, Anne Y Warren, Kelly A Holmes, Gerard A Tarulli, Wayne D Tilley, Benita S Katzenellenbogen, John R Hawse, Vincent J Gnanapragasam, Jason S Carroll

Molecular and Cellular Endocrinology | ELSEVIER IRELAND LTD | Published : 2017

Abstract

Estrogen Receptor-β (ERβ) has been implicated in many cancers. In prostate and breast cancer its function is controversial, but genetic studies implicate a role in cancer progression. Much of the confusion around ERβ stems from antibodies that are inadequately validated, yet have become standard tools for deciphering its role. Using an ERβ-inducible cell system we assessed commonly utilized ERβ antibodies and show that one of the most commonly used antibodies, NCL-ER-BETA, is non-specific for ERβ. Other antibodies have limited ERβ specificity or are only specific in one experimental modality. ERβ is commonly studied in MCF-7 (breast) and LNCaP (prostate) cancer cell lines, but we found no ER..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Medical Research Council


Awarded by Urology Foundation Scholarship


Awarded by National Health and Medical Research Council of Australia


Awarded by Cancer Australia/National Breast Cancer Foundation


Awarded by National Breast Cancer Foundation Pilot Study


Awarded by Prostate Cancer Research Program Transformative Impact Award from the US Department of Defense


Awarded by Cancer Research UK


Awarded by The Urology Foundation


Funding Acknowledgements

AWN is supported by The Medical Research Council (MR/L00156X/1) and The Urology Foundation Scholarship (RESCH1302). WDT is supported by the National Health and Medical Research Council of Australia (ID 1008349 and 1084416), Cancer Australia/National Breast Cancer Foundation (ID 1043497), National Breast Cancer Foundation Pilot Study (PS-15-041) and a Prostate Cancer Research Program Transformative Impact Award from the US Department of Defense (W81XWH-13-2-0093). BSK receives a grant from the Breast Cancer Research Foundation. JSC is funded by Cancer Research UK and an ERC Consolidator award.